DDrare: Database of Drug Development for Rare Diseases

Searched query = "Huntington disease", "Huntington chorea"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = (2)-epigallocatechin-3-gallate (EGCG); 20 mg BID of PF-02545920; 20mg daily citalopram; 5-Chloro-1,2-dihydro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide sodium; ACR16; ACR16 10 mg; ACR16 22.5 mg; ACR16 45 mg; ACR16 hydrochloride, ASP2314 hydrochloride, FR310826; AFQ056; ANX005; Alprazolam; Amantadine; Anti-Parkinson medication; Atomoxetine; Autologous Stem Cell; BEVANTOLOL HYDROCHLORIDE; BN82451B; BN8251B; Bevantolol; Biotin; Blood sample; Bupropion; CBD; CKD-504; CYSTAGON; Calvan® 100 mg; Cannabidiol; Cellavita HD Higher dose; Cellavita HD Lower Dose; Cellavita HD higher dose; Cellavita HD lower dose; Cellavita-HD; Citalopram; CoQ10; Coenzyme Q10; Creatine; Creatine Monohydrate; Creatine monohydrate; Cystagon; Cysteamine; Cysteamine Bitartrate; DM; Delta-9-tetrahydrocannabinol; Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD); Deutetrabenazine; Deutetrabenazine Oral Tablet [Austedo]; Device: BioStamp nPoint device; Device: Deep Brain Stimulation; Dextromethorphan; Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg); Digoxin; Dimebon; Dimebon (latrepirdine); Dimebon + Dextromethorphan; Dimebon + Ketoconazole; Dimebon + Omeprazole; Dimebon Dihydrochloride; Dimebon IR; Dimebon IR Tablet; Dimebon MR1; Dimebon MR2; Dimebon MR3; Dimebon MR4; Dimebon Transdermal; Dimebon alone; Dimebon dihydrochloride; Divalproex; EGCG; EPA; Epigallocatechin; Ethyl Icosapent; Ethyl-EPA; Ethyl-EPA (Miraxion™); Ethyl-Icosapent; Fenofibrate; GSK356278; Graft intracerebral of foetal neurons; HYPERIUM; Haloperidol; High doses of Thiamine y Biotin; Hyperium; ISIS 443139 10 mg; ISIS 443139 120 mg; ISIS 443139 30 mg; ISIS 443139 60 mg; ISIS 443139 90 mg; Icosapent; Ketoconazole; LAQUINIMOD; LAX-101; Laquinimod; Laquinimod capsules 0.5 mg; Latrepirdine; Lithium; Melatonin; Memantine; Minocycline; Moderate doses of Thiamine y Biotin; N.a.; Neflamapimod; Nilotinib; Nilotinib 150 MG; OMS643762; OSU6162 similar to (-)-OSU 6162; Olanzapine; Omeprazole; Other: 31-Phosphorus RMN Spectroscopy; PBF-999; PBF-999 / 160 mg; PBF-999 / 320 mg; PBT2; PF-02545920; PL101; PRIDOPIDINE HYDROCHLORIDE; Phenylbutyrate; Phosphorus; Pridiopidine; Pridopidina; Pridopidine; Pridopidine (90 mg); Quinidine; RG6042, formerly ISIS 443139, IONIS-HTTRx; RO7234292; RO7234292 (RG6042); RP 103; RP103; Ramelteon; Resveratrol; Rilmenidine; Riluzole; Risperidone; Ro 723-4292/F02; Rolipram; SAGE-718; SBT-020; SD-809; SEN0014196; SEN0014196 (High Dose); SEN0014196 (Low Dose); SOM3355 100mg BID; SOM3355 200mg BID; SRX246; SS-20; Selisistat; Sodium phenylbutyrate; THC; TV-5600; TV-7820; Tetrabenazine; Tetrabenazine withdrawal; Tetrahydrocannabinol; Thiamine; Tiapridal; Tominersen; Triheptanoin; Triheptanoin 1g/kg/day; Triheptanoin oil; UX007; Ubiquinol; Ursodiol; VX-745; VX15/2503; Valbenazine; WVE-120101; WVE-120102; Warfarin; Xenazine; Zoloft; [123I]MNI-420; [18F]FPEB

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-003637-42-DE (EUCTR)	28/07/2020	09/06/2020	A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s Disease	A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s Disease	Huntington's Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Product Name: WVE-120101 Product Code: WVE-120101 INN or Proposed INN: WVE-120101	Wave Life Sciences UK Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	50	Phase 2	France;Canada;Poland;Denmark;Australia;Germany;United Kingdom
2	EUCTR2019-003637-42-DK (EUCTR)	06/07/2020	02/03/2020	A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s Disease	A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s Disease	Huntington's Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 20.1;Level: LLT;Classification code 10012278;Term: Dementia due to Huntington's disease;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Product Name: WVE-120101 Product Code: WVE-120101 INN or Proposed INN: WVE-120101	Wave Life Sciences UK Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	50	Phase 2	France;Canada;Poland;Australia;Denmark;Germany;United Kingdom
3	NCT04617847 (ClinicalTrials.gov)	April 13, 2020	30/10/2020	Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease	A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients With Huntington's Disease	Huntington Disease	Drug: WVE-120101	Wave Life Sciences Ltd.	NULL	Enrolling by invitation	N/A	N/A	All	60	Phase 1;Phase 2	Australia;Canada;Denmark;France;Germany;Poland;United Kingdom
4	EUCTR2019-003637-42-PL (EUCTR)	11/04/2020	19/02/2020	A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s Disease	A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s Disease	Huntington's Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Product Name: WVE-120101 Product Code: WVE-120101 INN or Proposed INN: WVE-120101	Wave Life Sciences UK Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	50	Phase 2	France;Canada;Poland;Denmark;Australia;Germany;United Kingdom
5	EUCTR2016-005095-10-FR (EUCTR)	11/07/2019	05/03/2019	A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease	A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease	Huntington's Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]		Wave Life Science Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	48	Phase 1;Phase 2	United States;France;Canada;Poland;Denmark;Australia;Germany;United Kingdom
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	EUCTR2016-005095-10-DK (EUCTR)	26/02/2019	20/12/2018	A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease	A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease	Huntington's Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Product Name: WVE-120101 Product Code: WVE-120101 INN or Proposed INN: WVE-120101	Wave Life Sciences UK Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 1;Phase 2	France;Canada;Poland;Australia;Denmark;Germany;United Kingdom
7	EUCTR2016-005095-10-GB (EUCTR)	02/08/2018	17/10/2017	A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease	A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease	Huntington's Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]		Wave Life Sciences UK Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 1;Phase 2	France;United States;Canada;Poland;Denmark;Australia;Germany;United Kingdom
8	NCT03225833 (ClinicalTrials.gov)	July 17, 2017	17/7/2017	Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease	A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients With Huntington's Disease	Huntington's Disease	Drug: WVE-120101;Drug: Placebo	Wave Life Sciences Ltd.	NULL	Recruiting	25 Years	65 Years	All	60	Phase 1;Phase 2	Australia;Canada;Denmark;France;Germany;Poland;United Kingdom
9	EUCTR2016-005095-10-DE (EUCTR)		04/06/2019	A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease	A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease	Huntington's Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Product Name: WVE-120101 Product Code: WVE-120101 INN or Proposed INN: WVE-120101	Wave Life Sciences UK Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 1;Phase 2	France;Canada;Poland;Denmark;Australia;Germany;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2019-003637-42-DE
(EUCTR)

28/07/2020

09/06/2020

A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s Disease

Product Name: WVE-120101
Product Code: WVE-120101
INN or Proposed INN: WVE-120101

Wave Life Sciences UK Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

France;Canada;Poland;Denmark;Australia;Germany;United Kingdom

EUCTR2019-003637-42-DK
(EUCTR)

06/07/2020

02/03/2020

A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s Disease

Huntington's Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 20.1;Level: LLT;Classification code 10012278;Term: Dementia due to Huntington's disease;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]

Product Name: WVE-120101
Product Code: WVE-120101
INN or Proposed INN: WVE-120101

Wave Life Sciences UK Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

France;Canada;Poland;Australia;Denmark;Germany;United Kingdom

NCT04617847
(ClinicalTrials.gov)

April 13, 2020

30/10/2020

Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease

A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients With Huntington's Disease

Huntington Disease

Drug: WVE-120101

Wave Life Sciences Ltd.

NULL

Enrolling by invitation

N/A

All

Phase 1;Phase 2

Australia;Canada;Denmark;France;Germany;Poland;United Kingdom

EUCTR2019-003637-42-PL
(EUCTR)

11/04/2020

19/02/2020

A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s Disease

Product Name: WVE-120101
Product Code: WVE-120101
INN or Proposed INN: WVE-120101

Wave Life Sciences UK Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

France;Canada;Poland;Denmark;Australia;Germany;United Kingdom

EUCTR2016-005095-10-FR
(EUCTR)

11/07/2019

05/03/2019

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease

Wave Life Science Ltd.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 1;Phase 2

United States;France;Canada;Poland;Denmark;Australia;Germany;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2016-005095-10-DK
(EUCTR)

26/02/2019

20/12/2018

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease

Product Name: WVE-120101
Product Code: WVE-120101
INN or Proposed INN: WVE-120101

Wave Life Sciences UK Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 1;Phase 2

France;Canada;Poland;Australia;Denmark;Germany;United Kingdom

EUCTR2016-005095-10-GB
(EUCTR)

02/08/2018

17/10/2017

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease

Wave Life Sciences UK Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 1;Phase 2

France;United States;Canada;Poland;Denmark;Australia;Germany;United Kingdom

NCT03225833
(ClinicalTrials.gov)

July 17, 2017

17/7/2017

Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients With Huntington's Disease

Huntington's Disease

Drug: WVE-120101;Drug: Placebo

Wave Life Sciences Ltd.

NULL

Recruiting

25 Years

65 Years

All

Phase 1;Phase 2

Australia;Canada;Denmark;France;Germany;Poland;United Kingdom

EUCTR2016-005095-10-DE
(EUCTR)

04/06/2019

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease

Product Name: WVE-120101
Product Code: WVE-120101
INN or Proposed INN: WVE-120101

Wave Life Sciences UK Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 1;Phase 2

France;Canada;Poland;Denmark;Australia;Germany;United Kingdom